Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test dapagliflizone in Fabry patients. The main
questions it aims to answer are:
- Has 10 mg/d of dapagliflozin a positive effect on kidney functions of Fabry patients.
- Has 10 mg/d of dapagliflozin a positive effect on heart functions in Fabry patients.
Participants will be asked to
- Sign an informed consent
- Give a blood and urine samples
- Be subjected to Echocardiography investigation
- Take 10 mg/day Dapagliflizone
Researchers will compare treatment to placebo groups to see if kidneys and heart functions
will be improved in the treatment group better more than the placebo group.